These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6992759)

  • 21. [Insulin, glucagon and C-peptide content in the blood of acromegaly patients].
    Molitvoslovova NN
    Probl Endokrinol (Mosk); 1983; 29(3):21-4. PubMed ID: 6346317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin, glucagon, and amino acids during glycemic control by the artificial pancreas in diabetic man.
    Hanna AK; Zinman B; Nakhooda AF; Minuk HL; Stokes EF; Albisser AM; Leibel BS; Marliss EB
    Metabolism; 1980 Apr; 29(4):321-32. PubMed ID: 6990172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
    Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Ehlers MR; Egan JM; Elahi D
    Diabetes Care; 2003 Mar; 26(3):837-42. PubMed ID: 12610046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of glucose on the glucagon response to L-dopa in normal and diabetic subjects.
    Klimes I; Vigas M; Jurcovicová J; Repceková D; Kolesár P
    Diabetes; 1978 Apr; 27(4):396-9. PubMed ID: 640244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Blood serum levels of C-peptide and insulin in diabetics and healthy persons after intravenous administration of glucagon and glucose].
    Jayyab AK; Heding LG; Czyzyk A; Malczewski B; Krókewski AS
    Pol Arch Med Wewn; 1980 Sep; 64(3):229-38. PubMed ID: 7003563
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.
    Hendriksen C; Faber OK; Drejer J; Binder C
    Diabetologia; 1977 Dec; 13(6):615-9. PubMed ID: 338408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics.
    Christensen SE; Hansen AP; Weeke J; Lundbaek K
    Diabetes; 1978 Mar; 27(3):300-6. PubMed ID: 640235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcitonin, a diabetogenic hormone?
    Passariello N; Giugliano D; Sgambato S; Torella R; D'Onofrio F
    J Clin Endocrinol Metab; 1981 Aug; 53(2):318-23. PubMed ID: 7019230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas.
    Lenti G; Trovati M; Lorenzati R; Vitelli F; Tagliaferro V; Marocco A; Pagano G
    Acta Diabetol Lat; 1980; 17(1):9-14. PubMed ID: 6106342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
    Faber OK; Binder C
    Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.
    Bonora E; Cigolini M; Bosello O; Zancanaro C; Capretti L; Zavaroni I; Coscelli C; Butturini U
    Curr Med Res Opin; 1984; 9(1):47-51. PubMed ID: 6373159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects.
    Laager R; Keller U
    Diabetologia; 1993 Oct; 36(10):966-71. PubMed ID: 8243878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pancreatic hormone secretion in patients with newly detected diabetes mellitus].
    Belovalova IM; Kniazeva AP; Starosel'tseva LK; Perelygina AA
    Probl Endokrinol (Mosk); 1988; 34(6):3-6. PubMed ID: 3070538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The intra-nasal administration of insulin induces significant hypoglycaemia and classical counterregulatory hormonal responses in normal man.
    Paquot N; Scheen AJ; Franchimont P; Lefebvre PJ
    Diabete Metab; 1988; 14(1):31-6. PubMed ID: 3292305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
    Montgomery TM; Nelson RW; Feldman EC; Robertson K; Polonsky KS
    J Vet Intern Med; 1996; 10(3):116-22. PubMed ID: 8743209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.